{"id":"https://openalex.org/W1143596833","doi":"https://doi.org/10.1007/s10928-015-9435-z","title":"Modeling population heterogeneity in viral dynamics for chronic hepatitis C infection: Insights from Phase 3 telaprevir clinical studies","display_name":"Modeling population heterogeneity in viral dynamics for chronic hepatitis C infection: Insights from Phase 3 telaprevir clinical studies","publication_year":2015,"publication_date":"2015-08-19","ids":{"openalex":"https://openalex.org/W1143596833","doi":"https://doi.org/10.1007/s10928-015-9435-z","mag":"1143596833","pmid":"https://pubmed.ncbi.nlm.nih.gov/26289844"},"language":"en","primary_location":{"id":"doi:10.1007/s10928-015-9435-z","doi":"https://doi.org/10.1007/s10928-015-9435-z","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s10928-015-9435-z","pdf_url":null,"source":{"id":"https://openalex.org/S161302385","display_name":"Journal of Pharmacokinetics and Pharmacodynamics","issn_l":"1567-567X","issn":["1567-567X","1573-8744"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Pharmacokinetics and Pharmacodynamics","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5064938391","display_name":"Eric L. Haseltine","orcid":"https://orcid.org/0000-0002-3172-6299","observed_orcids":["https://orcid.org/0000-0002-3172-6299"]},"institutions":[{"id":"https://openalex.org/I61970326","display_name":"Vertex Pharmaceuticals (United States)","ror":"https://ror.org/00anb1726","country_code":"US","type":"company","lineage":["https://openalex.org/I61970326"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Eric L. Haseltine","raw_affiliation_strings":["Vertex Pharmaceuticals Incorporated, 50 Northern Ave., Boston, MA, 02210, United States. eric_haseltine@vrtx.com","Vertex Pharmaceuticals, Inc., Boston, United States"],"raw_orcid":"https://orcid.org/0000-0002-3172-6299","affiliations":[{"raw_affiliation_string":"Vertex Pharmaceuticals Incorporated, 50 Northern Ave., Boston, MA, 02210, United States. eric_haseltine@vrtx.com","institution_ids":["https://openalex.org/I61970326"]},{"raw_affiliation_string":"Vertex Pharmaceuticals, Inc., Boston, United States","institution_ids":["https://openalex.org/I61970326"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001045301","display_name":"Holly H. C. Kimko","orcid":"https://orcid.org/0000-0003-1456-4862","observed_orcids":["https://orcid.org/0000-0003-1456-4862"]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Holly Kimko","raw_affiliation_strings":["Janssen Research & Development, Raritan, NJ, United States","Janssen Research & Development, Raritan, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research & Development, Raritan, NJ, United States","institution_ids":["https://openalex.org/I4405282460"]},{"raw_affiliation_string":"Janssen Research & Development, Raritan, United States","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109196861","display_name":"Haobin Luo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210137149","display_name":"Renewable Energy Systems (United States)","ror":"https://ror.org/036gc1b60","country_code":"US","type":"company","lineage":["https://openalex.org/I4210090535","https://openalex.org/I4210137149"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Haobin Luo","raw_affiliation_strings":["RES Group, Cambridge, MA, United States","RES Group, Cambridge, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"RES Group, Cambridge, MA, United States","institution_ids":["https://openalex.org/I4210137149"]},{"raw_affiliation_string":"RES Group, Cambridge, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081525978","display_name":"John Tolsma","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210137149","display_name":"Renewable Energy Systems (United States)","ror":"https://ror.org/036gc1b60","country_code":"US","type":"company","lineage":["https://openalex.org/I4210090535","https://openalex.org/I4210137149"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Tolsma","raw_affiliation_strings":["RES Group, Cambridge, MA, United States","RES Group, Cambridge, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"RES Group, Cambridge, MA, United States","institution_ids":["https://openalex.org/I4210137149"]},{"raw_affiliation_string":"RES Group, Cambridge, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111554926","display_name":"Doug J. Bartels","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I61970326","display_name":"Vertex Pharmaceuticals (United States)","ror":"https://ror.org/00anb1726","country_code":"US","type":"company","lineage":["https://openalex.org/I61970326"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Doug J. Bartels","raw_affiliation_strings":["Vertex Pharmaceuticals Incorporated, 50 Northern Ave., Boston, MA, 02210, United States","Vertex Pharmaceuticals, Inc., Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vertex Pharmaceuticals Incorporated, 50 Northern Ave., Boston, MA, 02210, United States","institution_ids":["https://openalex.org/I61970326"]},{"raw_affiliation_string":"Vertex Pharmaceuticals, Inc., Boston, United States","institution_ids":["https://openalex.org/I61970326"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057269368","display_name":"Tara L. Kieffer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I61970326","display_name":"Vertex Pharmaceuticals (United States)","ror":"https://ror.org/00anb1726","country_code":"US","type":"company","lineage":["https://openalex.org/I61970326"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tara L. Kieffer","raw_affiliation_strings":["Vertex Pharmaceuticals Incorporated, 50 Northern Ave., Boston, MA, 02210, United States","Vertex Pharmaceuticals, Inc., Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vertex Pharmaceuticals Incorporated, 50 Northern Ave., Boston, MA, 02210, United States","institution_ids":["https://openalex.org/I61970326"]},{"raw_affiliation_string":"Vertex Pharmaceuticals, Inc., Boston, United States","institution_ids":["https://openalex.org/I61970326"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5066575140","display_name":"Varun Garg","orcid":"https://orcid.org/0000-0002-9310-0005","observed_orcids":["https://orcid.org/0000-0002-9310-0005"]},"institutions":[{"id":"https://openalex.org/I61970326","display_name":"Vertex Pharmaceuticals (United States)","ror":"https://ror.org/00anb1726","country_code":"US","type":"company","lineage":["https://openalex.org/I61970326"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Varun Garg","raw_affiliation_strings":["Vertex Pharmaceuticals Incorporated, 50 Northern Ave., Boston, MA, 02210, United States","Vertex Pharmaceuticals, Inc., Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vertex Pharmaceuticals Incorporated, 50 Northern Ave., Boston, MA, 02210, United States","institution_ids":["https://openalex.org/I61970326"]},{"raw_affiliation_string":"Vertex Pharmaceuticals, Inc., Boston, United States","institution_ids":["https://openalex.org/I61970326"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5064938391"],"corresponding_institution_ids":["https://openalex.org/I61970326"],"apc_list":{"value":4390,"currency":"USD","value_usd":4390},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.01628247,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"42","issue":"6","first_page":"681","last_page":"698"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10151","display_name":"Hepatitis C virus research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10151","display_name":"Hepatitis C virus research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10482","display_name":"Mathematical and Theoretical Epidemiology and Ecology Models","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hepatitis-c-virus","display_name":"hepatitis C virus","score":0.7490000128746033},{"id":"https://openalex.org/keywords/telaprevir","display_name":"telaprevir","score":0.8169999718666077},{"id":"https://openalex.org/keywords/population-heterogeneity","display_name":"population heterogeneity","score":0.8339999914169312},{"id":"https://openalex.org/keywords/direct-acting-antivirals","display_name":"direct-acting antivirals","score":0.8330000042915344},{"id":"https://openalex.org/keywords/pegylated-interferon-alpha","display_name":"pegylated interferon-alpha","score":0.9100000262260437},{"id":"https://openalex.org/keywords/ribavirin","display_name":"ribavirin","score":0.9929999709129333},{"id":"https://openalex.org/keywords/dosing-regimen-comparison","display_name":"dosing regimen comparison","score":0.7200000286102295},{"id":"https://openalex.org/keywords/sustained-virologic-response","display_name":"sustained virological response","score":0.8740000128746033},{"id":"https://openalex.org/keywords/viral-breakthrough","display_name":"viral breakthrough","score":0.9739999771118164},{"id":"https://openalex.org/keywords/viral-sequence-data","display_name":"viral sequence data","score":0.4909999966621399},{"id":"https://openalex.org/keywords/interferon-response","display_name":"interferon response","score":0.734000027179718},{"id":"https://openalex.org/keywords/chronic-hepatitis-c","display_name":"chronic hepatitis C","score":0.625}],"concepts":[{"id":"https://openalex.org/C2778159067","wikidata":"https://www.wikidata.org/wiki/Q408557","display_name":"Telaprevir","level":5,"score":0.9163795709609985},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.8114205002784729},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.7526900768280029},{"id":"https://openalex.org/C2780040827","wikidata":"https://www.wikidata.org/wiki/Q421862","display_name":"Ribavirin","level":4,"score":0.7088109254837036},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.6163679361343384},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5788623094558716},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.5375767350196838},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.493307501077652},{"id":"https://openalex.org/C2776461080","wikidata":"https://www.wikidata.org/wiki/Q7160835","display_name":"Pegylated interferon","level":5,"score":0.463080495595932},{"id":"https://openalex.org/C2776408679","wikidata":"https://www.wikidata.org/wiki/Q708693","display_name":"Hepatitis C virus","level":3,"score":0.39299070835113525},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3836796283721924},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3750477433204651},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3394618630409241},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.1933271288871765},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005838","descriptor_name":"Genotype","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008954","descriptor_name":"Models, Biological","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D009842","descriptor_name":"Oligopeptides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D012254","descriptor_name":"Ribavirin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D012367","descriptor_name":"RNA, Viral","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015233","descriptor_name":"Models, Statistical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D015415","descriptor_name":"Biomarkers","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D016174","descriptor_name":"Hepacivirus","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D016174","descriptor_name":"Hepacivirus","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D016174","descriptor_name":"Hepacivirus","qualifier_ui":"Q000472","qualifier_name":"pathogenicity","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D016903","descriptor_name":"Drug Monitoring","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017326","descriptor_name":"Clinical Trials, Phase III as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D017711","descriptor_name":"Nonlinear Dynamics","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019562","descriptor_name":"Viral Load","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019698","descriptor_name":"Hepatitis C, Chronic","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D019698","descriptor_name":"Hepatitis C, Chronic","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D019698","descriptor_name":"Hepatitis C, Chronic","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D019698","descriptor_name":"Hepatitis C, Chronic","qualifier_ui":"Q000821","qualifier_name":"virology","is_major_topic":false},{"descriptor_ui":"D024882","descriptor_name":"Drug Resistance, Viral","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1007/s10928-015-9435-z","doi":"https://doi.org/10.1007/s10928-015-9435-z","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s10928-015-9435-z","pdf_url":null,"source":{"id":"https://openalex.org/S161302385","display_name":"Journal of Pharmacokinetics and Pharmacodynamics","issn_l":"1567-567X","issn":["1567-567X","1573-8744"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Pharmacokinetics and Pharmacodynamics","raw_type":"journal-article"},{"id":"pmid:26289844","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26289844","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of pharmacokinetics and pharmacodynamics","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":27,"referenced_works":["https://openalex.org/W204086469","https://openalex.org/W1533844646","https://openalex.org/W1979862324","https://openalex.org/W1989062739","https://openalex.org/W1996596333","https://openalex.org/W1996603373","https://openalex.org/W2004998717","https://openalex.org/W2014954855","https://openalex.org/W2043519223","https://openalex.org/W2057075704","https://openalex.org/W2063698062","https://openalex.org/W2075531822","https://openalex.org/W2088421586","https://openalex.org/W2089138082","https://openalex.org/W2106378149","https://openalex.org/W2107512529","https://openalex.org/W2125963799","https://openalex.org/W2133578465","https://openalex.org/W2137008167","https://openalex.org/W2141214317","https://openalex.org/W2141317928","https://openalex.org/W2147322502","https://openalex.org/W2164211111","https://openalex.org/W2164439784","https://openalex.org/W2168579451","https://openalex.org/W2169951238","https://openalex.org/W2462516126"],"related_works":["https://openalex.org/W2089138082","https://openalex.org/W1979862324","https://openalex.org/W2558510450","https://openalex.org/W2896442443","https://openalex.org/W2540335334","https://openalex.org/W1495139370","https://openalex.org/W1989062739","https://openalex.org/W2060441409","https://openalex.org/W2004560175","https://openalex.org/W1708731269"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}